Ammakkanavar, Natraj Reddy
Community Health Network
4 papers on CoChat
Most cited papers
- Verified
Phase II Trial of Pembrolizumab in Patients with Platinum Refractory Germ-Cell Tumors: A Hoosier Cancer Research Network Study GU14-206
Adra, N., Einhorn, L. H., Althouse, S. K., Ammakkanavar, N. R., Musapatika, D., Albany, C., Vaughn, D., & Hanna, N. H. (2018) · Annals of Oncology
Testicular diseases and treatmentsCancer Immunotherapy and Biomarkers
Cited by 196
- Verified
Clinical benefit of a precision medicine based approach for guiding treatment of refractory cancers
Radovich, M., Kiel, P. J., Nance, S. M., Niland, E. E., Parsley, M. E., Ferguson, M. E., Jiang, G., Ammakkanavar, N. R., Einhorn, L. H., Cheng, L., et al. (2016) · Oncotarget
Cancer Genomics and DiagnosticsLung Cancer Treatments and Mutations
Cited by 111
- Verified
Pan-tumor activity of olomorasib (LY3537982), a second-generation KRAS G12C inhibitor (G12Ci), in patients with KRAS G12C-mutant advanced solid tumors.
Heist, R. S., Koyama, T., Murciano-Goroff, Y. R., Hollebecque, A., Cassier, P. A., Han, J.-Y., Tosi, D., Sacher, A. G., Burns, T. F., Spira, A. I., et al. (2024) · Journal of Clinical Oncology
Protein Kinase Regulation and GTPase SignalingLung Cancer Treatments and Mutations
Cited by 48
- Verified
Abstract CT028: A first-in-human phase 1 study of LY3537982, a highly selective and potent KRAS G12C inhibitor in patients with KRAS G12C-mutant advanced solid tumors
Murciano-Goroff, Y. R., Heist, R. S., Kuboki, Y., Koyama, T., Ammakkanavar, N. R., Hollebecque, A., Patnaik, A., Shimizu, T., Spira, A. I., Nagasaka, M., et al. (2023) · Cancer Research
Lung Cancer Treatments and MutationsProtein Kinase Regulation and GTPase Signaling
Cited by 40
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free